DSMB recommended study suspension slow accrual

This Phase III trial four treatment strategies non-critically ill hospitalized participants (not requiring intensive care unit (ICU) admission and/or mechanical ventilation) with SARS CoV-2 infection, Participants will receive hydroxychloroquine or chloroquine with or without azithromycin.

This Phase III trial will utilize four treatment strategies in non-critically ill hospitalized participants (not requiring mechanical ventilation) with SARS CoV-2 infection, Participants will receive hydroxychloroquine or chloroquine with or without azithromycin. Investigators are primarily interested in the time to recovery. In addition to study medications there will be daily symptom surveys for 14 days, then weekly thereafter for 4 weeks resulting in a total duration of follow up of 42 days. During hospitalization, daily symptom surveys will be completed in conjunction with the study coordinators. On discharge participants will have the option to complete electronic symptom surveys or complete symptom surveys via telephone with study coordinator. In the event that the participant opts for electronic symptom surveys on discharge participants will in addition receive a follow up call from a study coordination every 7 days during the initial 14 day period. In addition, failure to submit a symptom survey will prompt a study follow up call. Data from standard of care SOC will be collected from medical records.

Inclusion Criteria:

• Hospitalization for management of SARS CoV-2 infection

• Positive SARS CoV-2 test

• Age >=18 years

• Provision of informed consent

• Electrocardiogram (ECG) ≤48 hours prior to enrollment

• Complete blood count, glucose-6 phosphate-dehydrogenase (G6PD), comprehensive metabolic panel and magnesium ≤48 hours prior to enrollment from standard of care.

• If participating in sexual activity that could lead to pregnancy, individuals of reproductive potential who can become pregnant must agree to use contraception throughout the study. At least one of the following must be used throughout the study:

  • Condom (male or female) with or without spermicide
  • Diaphragm or cervical cap with spermicide
  • Intrauterine device (IUD)
  • Hormone-based contraceptive

Exclusion Criteria:

• Contraindication or allergy to chloroquine, hydroxychloroquine or azithromycin

• Current use hydroxychloroquine, chloroquine or azithromycin

• Concurrent use of another investigational agent

• Invasive mechanical ventilation

• Participants who have any severe and/or uncontrolled medical conditions such as:

  • unstable angina pectoris,
  • symptomatic congestive heart failure,
  • myocardial infarction,
  • cardiac arrhythmias or know prolonged QTc >470 males, >480 female on ECG
  • pulmonary insufficiency,
  • epilepsy (interaction with chloroquine),

• Prior retinal eye disease

• Concurrent malignancy requiring chemotherapy

• Known Chronic Kidney disease, eGFR<10 or dialysis

• G-6-PD deficiency, if unknown requires G6PD testing prior to enrollment

  • Known Porphyria
  • Known myasthenia gravis
  • Currently pregnant or planning on getting pregnant while on study
  • Breast feeding
  • AST/ALT >five times the upper limit of normal ULN*
  • Bilirubin >five times the ULN*
  • Magnesium <1.4 mEq/L*
  • Calcium <8.4mg/dL >10.6mg/dL*
  • Potassium <3.3 >5.5 mEg/L*

6 weeks per participant

Enrollment in the clinical trial did not reach the target number of subjects needed to achieve target power and was insufficient to produce statistically reliable results.